These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 32772956

  • 21. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
    Chokka P, Bougie J, Proulx J, Tvistholm AH, Ettrup A.
    CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
    [Abstract] [Full Text] [Related]

  • 22. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME.
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [Abstract] [Full Text] [Related]

  • 23. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder.
    Wang G, Zhao K, Reynaud-Mougin C, Loft H, Ren H, Eriksen HF, Ettrup A.
    Curr Med Res Opin; 2020 May; 36(5):875-882. PubMed ID: 31990207
    [Abstract] [Full Text] [Related]

  • 24. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G, Wang X, Ma D.
    Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
    [Abstract] [Full Text] [Related]

  • 25. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
    Vieta E, Sluth LB, Olsen CK.
    J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A Taiwanese study on real-world evidence with vortioxetine in patients with major depression in Asia (TREVIDA).
    Yang YK, Chen CS, Tsai CF, Chang CM, Lai TJ, Lee CT, Lin CC, Lan TH, Herr KJ.
    Curr Med Res Opin; 2021 Dec; 37(12):2163-2173. PubMed ID: 34515596
    [Abstract] [Full Text] [Related]

  • 29. Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset.
    Iovieno N, Papakostas GI, Feeney A, Fava M, Mathew SJ, Iosifescu DI, Murrough JW, Macaluso M, Hock RS, Jha MK.
    J Clin Psychiatry; 2021 Jun 15; 82(4):. PubMed ID: 34133089
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis.
    Zheng J, Wang Z, Li E.
    Afr Health Sci; 2019 Mar 15; 19(1):1716-1726. PubMed ID: 31149002
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR, Jacobsen PL, Chen Y.
    Curr Med Res Opin; 2013 Mar 15; 29(3):217-26. PubMed ID: 23252878
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Minimal clinically important change in the MADRS anhedonia factor score: A pooled analysis of open-label studies with vortioxetine in patients with major depressive disorder.
    McIntyre RS, Necking O, Schmidt SN, Reines E.
    J Affect Disord; 2024 Oct 15; 363():430-435. PubMed ID: 39032712
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.